These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 38474208)

  • 21. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
    Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
    Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice.
    Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY
    J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iron aggravates hepatic insulin resistance in the absence of inflammation in a novel db/db mouse model with iron overload.
    Altamura S; Müdder K; Schlotterer A; Fleming T; Heidenreich E; Qiu R; Hammes HP; Nawroth P; Muckenthaler MU
    Mol Metab; 2021 Sep; 51():101235. PubMed ID: 33872860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
    Romero-Gómez M; Lawitz E; Shankar RR; Chaudhri E; Liu J; Lam RLH; Kaufman KD; Engel SS;
    J Hepatol; 2023 Oct; 79(4):888-897. PubMed ID: 37355043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD.
    Sabinari I; Horakova O; Cajka T; Kleinova V; Wieckowski MR; Rossmeisl M
    Physiol Res; 2024 Aug; 73(Suppl 1):S295-S320. PubMed ID: 39016154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease.
    Kjeldsen SAS; Werge MP; Grandt J; Richter MM; Thing M; Hetland LE; Rashu EB; Jensen AH; Winther-Sørensen M; Kellemann JS; Holst JJ; Junker AE; Serizawa RR; Vyberg M; Gluud LL; Wewer Albrechtsen NJ
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G558-G570. PubMed ID: 39104323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of Hepatocellular Fatty Acid Uptake in Mouse Models of Fatty Liver Disease with and without Functional Leptin Signaling: Roles of NfKB and SREBP-1C and the Effects of Spexin.
    Ge JF; Walewski JL; Anglade D; Berk PD
    Semin Liver Dis; 2016 Sep; 36(4):360-372. PubMed ID: 27997977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ginsenosides reduce body weight and ameliorate hepatic steatosis in high fat diet‑induced obese mice via endoplasmic reticulum stress and p‑STAT3/STAT3 signaling.
    Yao Y
    Mol Med Rep; 2020 Mar; 21(3):1059-1070. PubMed ID: 32016448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Semaglutide May Alleviate Hepatic Steatosis in T2DM Combined with NFALD Mice via miR-5120/ABHD6.
    Li R; Ye Z; She D; Fang P; Zong G; Hu K; Kong D; Xu W; Li L; Zhou Y; Zhang K; Xue Y
    Drug Des Devel Ther; 2022; 16():3557-3572. PubMed ID: 36238196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.
    McCrimmon RJ; Catarig AM; Frias JP; Lausvig NL; le Roux CW; Thielke D; Lingvay I
    Diabetologia; 2020 Mar; 63(3):473-485. PubMed ID: 31897524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
    Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver MicroRNA-291b-3p Promotes Hepatic Lipogenesis through Negative Regulation of Adenosine 5'-Monophosphate (AMP)-activated Protein Kinase α1.
    Meng X; Guo J; Fang W; Dou L; Li M; Huang X; Zhou S; Man Y; Tang W; Yu L; Li J
    J Biol Chem; 2016 May; 291(20):10625-34. PubMed ID: 27013659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.
    Volpe S; Lisco G; Fanelli M; Racaniello D; Colaianni V; Triggiani D; Donghia R; Crudele L; Rinaldi R; Sabbà C; Triggiani V; De Pergola G; Piazzolla G
    Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
    Everard A; Matamoros S; Geurts L; Delzenne NM; Cani PD
    mBio; 2014 Jun; 5(3):e01011-14. PubMed ID: 24917595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.
    Newsome P; Francque S; Harrison S; Ratziu V; Van Gaal L; Calanna S; Hansen M; Linder M; Sanyal A
    Aliment Pharmacol Ther; 2019 Jul; 50(2):193-203. PubMed ID: 31246368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic fatty acid and glucose handling in metabolic disease: Potential impact on cardiovascular disease risk.
    Westcott F; Dearlove DJ; Hodson L
    Atherosclerosis; 2024 Jul; 394():117237. PubMed ID: 37633797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Grape pomace reduces the severity of non-alcoholic hepatic steatosis and the development of steatohepatitis by improving insulin sensitivity and reducing ectopic fat deposition in mice.
    Daniel T; Ben-Shachar M; Drori E; Hamad S; Permyakova A; Ben-Cnaan E; Tam J; Kerem Z; Rosenzweig T
    J Nutr Biochem; 2021 Dec; 98():108867. PubMed ID: 34571189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.